(1R,2R)-N1-isopropylcyclohexane-1,2-diamine | 1204751-27-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (1R,2R)-N1-isopropylcyclohexane-1,2-diamine
• 英文别名: (1R,2R)-2-N-propan-2-ylcyclohexane-1,2-diamine
• CAS: 1204751-27-8
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: HOWZEUNOTJRFMB-RKDXNWHRSA-N

物化性质

• 沸点：
  204.6±8.0 °C(Predicted)
• 密度：
  0.90±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R,2R)-N1-isopropylcyclohexane-1,2-diamine 以 水 为溶剂， 反应 42.0h， 生成 cis-[(1R,2R)-N¹-isopropyl-1,2-diaminocyclohexane-N,N'][(+)-camphorato-O,O']platinum(II)
  参考文献：
  名称：

  Synthesis and biological evaluation of platinum(II) complexes containing (1R,2R)-N1-alkyl-1,2-diaminocyclohexane and D-(+)-camphorate ligands

  摘要：

  Five platinum(II) complexes with N-monoalkyl derivatives of 1R,2R-diaminocyclohexane as ligands and D-(+)-camphorate anion as leaving group have been synthesized and characterized by elemental analysis, IR, H-1 NMR, ESI-MS, and HRMS spectra. All complexes were evaluated for their in vitro cytotoxicity against four human tumor cell lines and most of them showed promising cytotoxic activity, especially compounds 3 and 4 with branched alkyl substituent at one of nitrogen atoms. Preliminary mechanism study by flow cytometry and agarose gel electrophoresis was also carried out in comparison with cisplatin and oxaliplatin. (C) 2012 Elsevier B. V. All rights reserved.

  DOI：

  10.1016/j.ica.2012.10.011
• 作为产物：
  描述：

  N-[(1R,2R)-2-(isopropylamino)cyclohexyl]benzamide 在 盐酸 、 sodium hydroxide 作用下， 以 水 、 二氯甲烷 为溶剂， 以98%的产率得到(1R,2R)-N1-isopropylcyclohexane-1,2-diamine
  参考文献：
  名称：

  用于不对称催化的仿生鸟嘌呤基有机催化剂的设计与开发

  摘要：

  介绍了一系列新型有机催化剂的设计、制备和研究。催化剂的设计灵感来自于 DNA 核碱基发展精确和明确的氢键的能力。我们已经表明，这种现象可用于创建一种有用的有机催化剂，该催化剂显示出类似于常见有机底物的识别模式。基于鸟嘌呤结构的选定双功能催化剂已被证明可催化 1,3-二羰基化合物与各种硝基烯烃的共轭加成，从而以良好的产率和对映选择性提供产品。

  DOI：

  10.1002/ejoc.201200118

文献信息

• Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors
  申请人：Babu Yarlagadda S.

  公开号：US20120149691A1

  公开（公告）日：2012-06-14

  The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.

  本发明提供公式I的化合物：或其盐，如本文所述。本发明还提供含有公式I化合物的药物组合物，制备公式I化合物的过程，用于制备公式I化合物的中间体，以及使用公式I化合物抑制免疫反应或治疗癌症或血液恶性肿瘤的治疗方法。
• 2, 6-NAPHTHRIDINE DERIVATIVES
  申请人：van Eis Maurice

  公开号：US20100130469A1

  公开（公告）日：2010-05-27

  The present invention relates to novel organic compounds comprising a naphthyridine which may be mediators of a selective subset of kinases belonging to the AGC kinase family, such as for example PKC, PKD, PKN-1/2, CDK-9, MRCK-beat, PASK, PRKX, ROCK-I/II or mediators of other kinases, the selectivity of which would be depending on the structural variation thereof.

  本发明涉及一种新的有机化合物，包括一种萘啶，它可能是AGC激酶家族的一种选择性亚组的介质，例如PKC，PKD，PKN-1/2，CDK-9，MRCK-beat，PASK，PRKX，ROCK-I/II或其他激酶的介质，其选择性取决于其结构变化。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20170275289A1

  公开（公告）日：2017-09-28

  The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R 1 , R 3 , R 4 , R 5 , and each R e have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
• COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：ENCEFA

  公开号：US20210087290A1

  公开（公告）日：2021-03-25

  A compound, which specifically binds to CD38, for use as a medicament in the prevention and/or treatment of a neurodegenerative disease and/or an inflammatory disease, by the opening of NAADP receptors Two Pore Channels TPC1 and/or TPC2, wherein the compound activates the opening of NAADP receptors Two Pore Channels TPC1 and/or TPC2.
• Design and Development of Bioinspired Guanine-Based Organic Catalyst for Asymmetric Catalysis
  作者：Gal Suez、Victoria Bloch、Gennady Nisnevich、Mark Gandelman

  DOI：10.1002/ejoc.201200118

  日期：2012.4

  Design, preparation, and studies of a family of new organic catalysts are presented. The design of the catalysts is inspired by the ability of DNA nucleobases to develop precise and explicit hydrogen bonds. We have shown that this phenomenon can be used to create a useful organic catalyst that demonstrates a recognition pattern similar to those of common organic substrates. A selected bifunctional

  介绍了一系列新型有机催化剂的设计、制备和研究。催化剂的设计灵感来自于 DNA 核碱基发展精确和明确的氢键的能力。我们已经表明，这种现象可用于创建一种有用的有机催化剂，该催化剂显示出类似于常见有机底物的识别模式。基于鸟嘌呤结构的选定双功能催化剂已被证明可催化 1,3-二羰基化合物与各种硝基烯烃的共轭加成，从而以良好的产率和对映选择性提供产品。